We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$53.5M
1-Year Est. Return
80.67%
This Fund
S&P 500
This Quarter
Est. Return
+13.03%
1 Year Est. Return
+80.67%
3 Year Est. Return
+80.2%
5 Year Est. Return
+49.87%
10 Year Est. Return
+446.13%
AUM
$53.3M
AUM Growth
-$4.76M
(-8.2%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-24.03%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$10.1M |
| 2 |
Sana Biotechnology
SANA
|
+$2.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.34% |
| 2 | Technology | 3.66% |
Similar funds
OM
ICCON
HCM
ETCM
IDBONY
PCM
TCDRS
FPAM
Crestline Management's Q4 2025 Portfolio in Review
As of Q4 2025, Crestline Management held 3 positions worth $53.3M, down 8.2% from $58.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Crestline Management withdrew a net $12.8M in Q4 2025, reducing 2 holdings. Its largest reduction was Denali Therapeutics, cutting an estimated $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology.
- Crestline Management's biggest Q4 2025 reduction was Denali Therapeutics, cutting an estimated $10.1M.
- Crestline Management's ten largest holdings make up 100% of its $53.3M portfolio in Q4 2025.
- Crestline Management opened 0 new positions and closed 0 in Q4 2025.
- Crestline Management's portfolio value fell 8.2% quarter-over-quarter to $53.3M.
Based on Crestline Management's 13F filing for Q4 2025, filed 17 Feb 2026.